Takeda Pharmaceutical Co. Ltd. has signed an option agreement to in-license Ascentage Pharma Group Inc.’s olverembatinib, an oral third-generation BCR-ABL tyrosine kinase inhibitor (TKI). If exercised, the option would allow Takeda to license exclusive global rights to develop and commercialize olverembatinib in all territories outside of mainland China, Hong Kong, Macau, Taiwan and Russia.
The development of resistance and relapse during the blast phase of chronic myeloid leukemia poses a challenge in the management of this pathology, with half of the cases accounting for FLT3 pathway activation that, in turn, contributes to tyrosine kinase inhibitor resistance.
Takeda Pharmaceutical Co. Ltd. has signed an option agreement to in-license Ascentage Pharma Group Inc.’s olverembatinib, an oral third-generation BCR-ABL tyrosine kinase inhibitor (TKI). If exercised, the option would allow Takeda to license exclusive global rights to develop and commercialize olverembatinib in all territories outside of mainland China, Hong Kong, Macau, Taiwan and Russia.
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by a chromosomal translocation that results in the generation of the BCR-ABL1 oncogene, which encodes the chimeric BCR-ABL1 protein with tyrosine kinase activity. Allosteric tyrosine kinase inhibitors (TKIs) represent an improvement of 2-fold in efficacy over standard inhibitors and are better tolerated.
Beijing Innocare Pharma Tech Co. Ltd. has divulged heterocyclic compounds acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for treatment of cancer.
Preliminary preclinical data have been reported for Enliven Therapeutics Inc.’s ATP-competitive small-molecule ABL1 tyrosine kinase inhibitor (TKI) ELVN-001. In vitro antiproliferative effects, assessed using the biomarker Tyr207-phosphorylated CRKL, demonstrated that ELVN-001 had potent activity with IC50 values ranging from 19 to 112 nM against BCR-ABL1-driven chronic myeloid leukemia (CML) cell lines in the presence of 50% to 100% human serum.
Lifearc has identified pyrimidine compounds acting as serine/threonine-protein kinase ULK inhibitors reported to be useful for the treatment of chronic myeloid leukemia.
Expanding its mandate to accelerate access to essential medicines to people in low- and middle-income countries, the Medicines Patent Pool signed its first voluntary licensing agreement for a cancer treatment, Novartis AG’s Tasigna (nilotinib).
Expanding its mandate to accelerate access to essential medicines to people in low- and middle-income countries, the Medicines Patent Pool signed its first voluntary licensing agreement for a cancer treatment, Novartis AG’s Tasigna (nilotinib). A twice-daily oral drug, Tasigna is a tyrosine kinase inhibitor included on the World Health Organization’s Model List of Essential Medicines as a second-line treatment for adult and pediatric chronic myeloid leukemia.
